Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Pozycja w akcjach #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Cena akcji
$0.00047446
Kapitalizacja rynkowa
$82.80
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-98.16%
Kraj
FR
Handel Neovacs S.A. (ALNEV)

Kategoria

Zyski dla Neovacs S.A. (ALNEV)
Zyski w Dec 2024 TTM: $-35.33M
Według najnowszych raportów finansowych Neovacs S.A., obecny zysk firmy wynosi $-35.33M. W roku 2023 firma osiągnęła zysk w wysokości $-10.63M, spadek w porównaniu do zysku z roku 2022, który wynosił $-4.66M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Neovacs S.A. od 2007 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-35.33M 0.00%
2024 $-35.33M 232.17%
2023 $-10.63M 128.13%
2022 $-4.66M -67.15%
2021 $-14.19M 74.31%
2020 $-8.14M -22.00%
2019 $-10.44M -33.00%
2018 $-15.58M -31.17%
2017 $-22.63M 24.13%
2016 $-18.23M 131.65%
2015 $-7.87M -33.75%
2014 $-11.88M 7.75%
2013 $-11.03M 0.62%
2012 $-10.96M -12.83%
2011 $-12.57M -8.71%
2010 $-13.77M 14.01%
2009 $-12.08M 72.06%
2008 $-7.02M -9.80%
2007 $-7.78M 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$20.51B -58,146.44%
DK
$4.64B -13,244.00%
US
$5.23B -14,907.10%
US
$2.14B -6,151.40%
BE
$1.45B -4,207.73%
NL